title: Effect of practitioner education on adherence to asthma treatment guidelines.
abstract: OBJECTIVE
  To determine whether a letter-based intervention program submitted to prescribers and pharmacists would improve drug therapy in users of high-dose beta(2)-agonists (HDBs).
  
  
  METHODS
  Retrospective drug utilization review.
  
  
  METHODS
  The intervention group consisted of 135 asthmatic patients (identified through ICD-9-CM codes) in the Connecticut Medicaid Program who submitted >1 claim per month for short-acting beta(2)-agonists (over a 6-mo period). Patient-specific intervention packets were mailed to the patients' prescribers and pharmacists, and their use of long-term control agents and healthcare utilization was evaluated over 6 months. These variables were compared with a comparison group (n = 510) of asthmatics drawn from the same Medicaid program who were not considered to be high-dose users of short-acting beta(2)-agonists at baseline.
  
  
  RESULTS
  Prior to the intervention, the intervention group used fewer long-term asthma control agents as compared with the comparison group (58% vs. 96%; p < 0.001); there was no significant difference after the intervention program (65% vs. 71%; p = 0.169). The acquisition of spacers was greater in the intervention group than in the control group after the intervention (7% vs. 2%; p = 0.007). At the end of the 6-month intervention period, 46% of patients in the intervention group were no longer HDB users (p < 0.001). The higher frequency of prescriber office visits in the intervention group than the comparison group before the intervention (0.46 +/- 0.82 vs. 0.25 +/- 0.66; p < 0.001) was not evident after the intervention program (0.24 +/- 0.63 vs. 0.18 +/- 0.60; p = 0.283).
  
  
  CONCLUSIONS
  This intervention program had modest impact on improving the use of long-term control agents and reducing prescriber office visits.
authors.affiliation: Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
authors.forename: Craig I
authors.initials: CI
authors.lastname: Coleman
authors.forename: Prabashni
authors.initials: P
authors.lastname: Reddy
authors.forename: N Michelle
authors.initials: NM
authors.lastname: Laster-Bradley
authors.forename: Sheila
authors.initials: S
authors.lastname: Dorval
authors.forename: Bharathi
authors.initials: B
authors.lastname: Munagala
authors.forename: C Michael
authors.initials: CM
authors.lastname: White
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D011307:Drug Prescriptions; D017723:Drug Utilization Review; D004501:Education, Medical; D005260:Female; D006801:Humans; D008297:Male; D008484:Medicaid; D008875:Middle Aged; D010595:Pharmacists; D012189:Retrospective Studies
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents